Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model.

Abstract

We present N-imidazopyridine-noscapinoids, a new class of noscapine derivatives that bind to tubulin and exhibit antiproliferative activity against triple positive (MCF-7) and triple negative (MDA-MB-231) breast cancer cells. The N-atom of the isoquinoline ring of noscapine scaffold was altered in silico by coupling the imidazo [(Ye et al., 1998; Ke et al., 2000) 1,21,2-a] pyridine pharmacophore to rationally develop a series of N-imidazopyridine-noscapinoids (7-11) with high tubulin binding affinity. The predicted ΔGbinding of the N-imidazopyridine-noscapinoids 7-11 varied from -27.45 to -36.15 kcal/mol, a much lower value than noscapine with ΔGbinding -22.49 kcal/mol. The cytotoxicity of N-imidazopyridine-noscapinoids was evaluated using hormone dependent MCF-7, triple negative MDA-MB-231 breast cancer cell lines and primary breast cancer cells. The cytotoxicity of these compounds (represented as IC50 concentration) ranges between 4.04 and 33.93 μM against breast cancer cells without affecting normal cells (IC50 value > 952 μM). All the compounds (7-11) perturbed the cell cycle progression at G2/M phase and triggered apoptosis. Among all the N-imidazopyridine-noscapinoids, N-5-Bromoimidazopyridine-noscapine (9) showed promising antiproliferative activity and was selected for detailed investigation. The onset of apoptosis treated with 9 using MDA-MB-231 revealed morphological changes like cellular shrinkage, chromatin condensation, membrane blebbing, and apoptotic bodies formation. Along with elevated reactive oxygen species (ROS), there was a loss of mitochondrial membrane potential, suggesting induction of apoptosis to cancer cells. Compound 9 was also found to significantly regress the implanted tumour in nude mice as xenografts of MCF-7 cells without any apparent side effects after drug administration. We conclude that N-imidazopyridine-noscapinoids possess excellent potential as a promising drug for treating breast cancers.

• Authors: Pratyush Pragyandipta, Ravi Kumar Pedapati, Praveen Kumar Reddy, Arnab Nayek, Rajesh Kumar Meher, Santosh Kumar Guru, Srinivas Kantevari, Pradeep K Naik
• Journal: Chemico-biological interactions (Chem Biol Interact) Vol. 382 Pg. 110606 (Sep 01 2023) ISSN: 1872-7786 [Electronic] Ireland
• PMID: 37330181 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier B.V. All rights reserved.

Chemical References

• Tubulin
• imidazopyridine
• Noscapine
• Antineoplastic Agents
• Pyridines

Topics

• Humans
• Animals
• Mice
• Female
• Tubulin (metabolism)
• Noscapine (pharmacology, therapeutic use)
• Heterografts
• Mice, Nude
• Microtubules
• Antineoplastic Agents (pharmacology, therapeutic use, chemistry)
• Pyridines (pharmacology, therapeutic use)
• Breast Neoplasms (pathology)
• Cell Proliferation
• Cell Line, Tumor
• Apoptosis